Introduction
============

Acute Type A aortic dissection (ATAAD) is a lethal cardiovascular emergency for which surgical repair is essential. [@JR180046-1] Despite significant improvements in perioperative management over the past decades, surgery for ATAAD is still associated with high mortality and morbidity. [@JR180046-2] Several factors, such as advanced age and comorbidities including diabetes and chronic obstructive pulmonary disease (COPD), preoperative cardiogenic shock with or without cardiac tamponade, and longer cardiopulmonary bypass (CPB) time, have been suggested as independent predictors of poor outcome. [@JR180046-3] [@JR180046-4] [@JR180046-5]

Sex differences have previously been shown to influence outcomes following cardiac surgery. [@JR180046-6] [@JR180046-7] In the risk models of both the Society of Thoracic Surgeons score and the European System for Cardiac Operative Risk Evaluation, female sex is a risk factor for early mortality after cardiac surgery. [@JR180046-6] [@JR180046-7] [@JR180046-8] In spite of sex differences being well documented in patients undergoing cardiac surgery, there have been few reports that specifically compare outcomes for males and females following surgical repair for ATAAD. Of the reported studies, some have found female sex to be an independent predictor of mortality after surgical repair for ATAAD, [@JR180046-3] [@JR180046-9] [@JR180046-10] while others found no significant association between sex and outcome. [@JR180046-4] [@JR180046-5] [@JR180046-11] The previous studies have been limited by small cohorts of heterogeneous study samples and have shown diverging results. This report from The Nordic Consortium for Acute Type A Dissection (NORCAAD) constitutes one of the largest studies investigating the impact of sex differences on outcome following surgical repair for ATAAD. The aim of this study was to determine the impact of sex on preoperative characteristics, operative management, and postoperative outcomes in a large multicenter cohort of patients who underwent surgical treatment for ATAAD.

Materials and Methods
=====================

The study is a part of NORCAAD, which includes eight centers in Denmark, Finland, Iceland, and Sweden. The study setup is further described elsewhere. [@JR180046-12] In brief, data were retrospectively collected for adult patients (\> 17 years of age) who underwent surgery for ATAAD between January 1, 2005 and December 31, 2014 at the following centers: Aarhus University Hospital, Skejby, Denmark; Karolinska University Hospital, Stockholm, Sweden; Landspitali University Hospital, Reykjavik, Iceland; Orebro University Hospital, Orebro, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Skane University Hospital, Lund, Sweden; Tampere University Hospital, Tampere, Finland; and Turku University Hospital, Turku, Finland. A total of 194 clinical variables were retrospectively collected, including demographics, past medical history, preoperative medications, clinical symptoms at presentation, methods of diagnosis, operative variables, complications, bleeding and blood transfusion, laboratory values, and outcome data. The length of stay was recorded as days in the intensive care unit and in the general ward.

The study was approved by each of the participating institutions. Patients were deidentified prior to inclusion into the database. As individual patients were not identified, obtaining individual consent for the study was waived.

Statistics
----------

Data were examined for normal distribution using the Shapiro--Wilk test. Comparisons of two groups were performed with Mann--Whitney U test for continuous variables. Nonordered categorical variables were compared with Pearson\'s chi-squared test and dichotomous variables with Fisher\'s exact test. All tests were two-tailed and conducted at a 0.05 significance level. Data are presented as mean ± standard deviation, median with 25th to 75th percentile (interquartile range) where applicable or number (percentage). Independent predictors of mortality were identified with odds ratio (OR) with 95% confidence interval (CI) estimated with a multivariable logistic regression. All variables were adjusted for age. The variables included in the multivariate analysis were selected based on degree of significance ( *p*  \< 0.20) from the univariate and age-adjusted analysis. All statistical analyses were performed by a professional statistician using SAS Software version 9.4 (SAS Institute Inc., Cary, NC).

Results
=======

A total of 1,154 patients were included in the study, of which 373 (32%) were females and 781 (68%) were males. The mean age for the cohort was 61 ± 12 years. Poisson regression and Cox proportional hazard analysis are found in the [Supplementary Tables 1](#SM180046-1){ref-type="supplementary-material"} and [2](#SM180046-1){ref-type="supplementary-material"} , respectively.

Patient Characteristics
-----------------------

Patient characteristics are outlined in [Table 1](#TB180046-1){ref-type="table"} . Females were significantly older (65 ± 11 vs. 60 ± 12 years, *p*  \< 0.001), had lower body mass index (BMI) (26 ± 5 vs. 27 ± 4 kg/m ^2^ , *p*  \< 0.001), and more often had a history of hypertension (58.9% vs. 48.3%, *p*  = 0.001) and COPD (8.3% vs. 4.9%, *p*  = 0.03) as compared with males. Furthermore, there was a trend toward increased rates of hypercholesterolemia (14.2% vs. 10.6%, *p*  = 0.09) and preoperative pericardial tamponade (19.2% vs. 15.7%, *p*  = 0.08) among females. Although within the normal range, females had lower preoperative creatinine levels than males (80 ± 28 vs. 106 ± 58 μmol/L, *p*  \< 0.001).

###### Patient characteristics

  ------------------------------------------------------------------------------------------------------------------
  Variables                          Male ( *n*  = 781)                Female ( *n*  = 373)             *p* -Value
  ---------------------------------- --------------------------------- -------------------------------- ------------
  Age                                59.9 (12.2) 62.0 (14.0; 86.0)\    65.0 (11.3) 66.0 (18.0; 85.0)\   \< 0.0001
                                     *n * = 781                        *n*  = 373                       

  Age \> 70 y                        157 (20.1%)                       134 (35.9%)                      \< 0.0001

  Body mass index                    27.2 (4.3) 26.2 (18.0; 47.7)\     25.8 (5.4) 24.8 (11.4; 53.9)\    \< 0.0001
                                     *n*  = 648                        *n*  = 308                       

  Smoking                            242 (44.2%)                       129 (43.0%)                      0.80

  Hypertension                       377 (48.3%)                       219 (58.9%)                      0.0010

  Hypercholesterolemia               82 (10.6%)                        53 (14.2%)                       0.092

  Diabetes mellitus II               15 (1.9%)                         11 (3.0%)                        0.37

  COPD                               38 (4.9%)                         31 (8.3%)                        0.033

  HxStroke                           30 (3.9%)                         17 (4.6%)                        0.67

  HxTIA                              14 (1.8%)                         3 (0.8%)                         0.29

  HxCKD                              17 (2.2%)                         4 (1.1%)                         0.28

  HxAfib                             23 (6.8%)                         4 (2.4%)                         0.052

  Marfan syndrome                    33 (4.2%)                         16 (4.3%)                        1.00

  Preoperative creatinine (µmol/L)   105.7 (57.9)95.0 (6.2; 1000.0)\   80.5 (28.2)75.0 (36.0; 285.0)\   \< 0.0001
                                     *n*  = 635                        *n*  = 324                       

  Euroscore II                       10.5 (11.2)7.3 (1.0; 65.4)\       9.35 (6.43)8.50 (0.62; 27.90)\   0.35
                                     *n*  = 219                        *n*  = 84                        

  LVEF TEE (%)                       49.1 (8.3)50.0 (0.5; 74.0)\       48.4 (8.6)50.0 (0.0; 70.0)\      0.37
                                     *n*  = 272                        *n*  = 130                       

  Cardiac arrest                     39 (5.0%)                         18 (4.8%)                        1.00

  Cardiogenic shock                  161 (22.3%)                       91 (26.1%)                       0.19

  Pericardial tamponade              120 (15.7%)                       70 (19.2%)                       0.17

  *DeBakey class:*                                                                                      

   I                                 596 (76.9%)                       247 (66.6%)                      

   II                                179 (23.1%)                       124 (33.4%)                      0.0003

  *Penn Class:*                                                                                         

   Penn Class A                      462 (59.7%)                       243 (65.7%)                      

   Penn Class B                      182 (23.5%)                       63 (17.0%)                       

   Penn Class C                      85 (11.0%)                        41 (11.1%)                       

   Penn Class B and C                45 (5.8%)                         23 (6.2%)                        0.092
  ------------------------------------------------------------------------------------------------------------------

Abbreviations: Afib, atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; Hx, history of; LVEF, left ventricular ejection fraction; SD, standard deviation; TEE, transthoracic echocardiogram; TIA, transient ischemic attack.

Note: Data are presented as *n* (%) or mean (SD) / median (min; max).

Perioperative Characteristics
-----------------------------

The perioperative characteristics are outlined in [Tables 2](#TB180046-2){ref-type="table"} and [3](#TB180046-3){ref-type="table"} . The median time from symptom presentation to definitive surgical treatment was 2.3 (1.0; 7.0) hours and 2.9 (1.0; 6.7) hours in females ( *n*  = 208) and males ( *n*  = 441), respectively ( *p*  = 0.72). However, data on time delay were missing in 165 (44%) females and 441 (56%) of males. Furthermore, females had shorter operation time (345 ± 133 vs. 374 ± 134.8 minutes, *p*  \< 0.001), CPB time (198 ± 77 vs. 212 ± 79 minutes, *p*  \< 0.001), aortic cross-clamp time (99 ± 54 vs. 109 ± 57 minutes, *p*  \< 0.001), and hypothermic circulatory arrest (HCA) time (28 ± 16 vs. 31 ± 19 minutes, *p*  = 0.02) as compared with males. In addition, significantly fewer females compared with males had surgical repair with a biological aortic valve replacement (3.8% vs. 7.1%, *p*  = 0.03) and less often underwent repair using a mechanical composite graft (10.2% vs. 21%, *p*  \< 0.001). Surgical repair with valve resuspension, however, was more common among females as compared with males (44.2% vs. 37.3%, *p*  = 0.001).

###### Intraoperative characteristics

  Variables                            Male ( *n*  = 781)                              Female ( *n*  = 373)                            *p* -Value
  ------------------------------------ ----------------------------------------------- ----------------------------------------------- ------------
  Operation time                       373.6 (134.8) 344.0 (36.0; 1059.0) *n*  = 627   344.8 (133.3) 310.0 (15.0; 1100.0) *n*  = 295   0.0001
  Cardiopulmonary bypass time          211.6 (79.0) 197.0 (0.0; 715.0) *n*  = 714      197.7 (77.4) 178.5 (22.0; 500.0) *n*  = 344     \< 0.0001
  Cardiac arrest time                  30.9 (18.8) 27.0 (0.0; 185.0) *n*  = 602        28.1 (16.5) 26.0 (0.0; 195.0) *n*  = 300        0.026
  Temperature at cardiac arrest        21.0 (4.9) 19.0 (11.0; 36.4) *n*  = 694         20.8 (4.6) 19.5 (13.0; 35.8) *n*  = 340         0.76
  Cross-clamp time                     109.2 (57.6) 96.0 (0.0; 363.0) *n * = 697       98.8 (53.9) 86.0 (1.0; 364.0) *n*  = 331        0.0012
  Biologic aortic valve                55 (7.1%)                                       14 (3.8%)                                       0.033
  *Proximal repair:*                                                                                                                   
   AV resuspension + ascending graft   291 (37.3%)                                     164 (44.2%)                                     
   AVR + ascending graft               25 (3.2%)                                       9 (2.4%)                                        
   Ascending graft only                220 (28.2%)                                     124 (33.4%)                                     
   Attempted                           7 (0.9%)                                        4 (1.1%)                                        
   Biological composite                43 (5.5%)                                       22 (5.9%)                                       
   Mechanical composite                164 (21.0%)                                     38 (10.2%)                                      
   Valve sparing root                  24 (3.1%)                                       8 (2.2%)                                        
   Ascending graft only prior AVR      6 (0.8%)                                        2 (0.5%)                                        0.0013
  *Distal repair:*                                                                                                                     
   Ascending aorta                     543 (70.3%)                                     269 (73.1%)                                     
   Attempted                           5 (0.6%)                                        5 (1.4%)                                        
   Hemiarch                            171 (22.2%)                                     77 (20.9%)                                      
   Total arch                          51 (6.6%)                                       15 (4.1%)                                       
   Other                               2 (0.3%)                                        2 (0.5%)                                        0.27
  Perioperative MI                     45 (5.9%)                                       26 (7.1%)                                       0.52
  Intraoperative death                 52 (6.7%)                                       34 (9.1%)                                       0.17

Abbreviations: AV, aortic valve; AVR, aortic valve replacement; MI, myocardial infarction; SD, standard deviation.

Note: Data are presented as *n* (%) or mean (SD) / median (min; max).

###### Postoperative characteristics

  Variables                      Male ( *n*  = 729)                          Female ( *n*  = 339)                       *p* -Value
  ------------------------------ ------------------------------------------- ------------------------------------------ ------------
  Reoperation bleeding           174 (23.9%)                                 56 (16.5%)                                 0.0050
  Length of stay in ICU          6.11 (8.45)4.00 (0.00; 134.00) *n*  = 568   5.23 (5.81)3.00 (0.00; 40.00) *n*  = 275   0.17
  Length of stay                 12.5 (12.6)9.0 (0.0; 136.0) *n*  = 492      12.9 (13.0)9.0 (0.0; 96.0) *n*  = 211      0.88
  Postoperative AF               289 (39.6%)                                 143 (42.2%)                                0.66
  Postoperative stroke           117 (16.0%)                                 60 (17.7%)                                 0.67
  Postoperative TIA              35 (4.8%)                                   17 (5.0%)                                  1.00
  Postoperative cardiac arrest   54 (7.4%)                                   24 (7.08%)                                 0.89
  Death at discharge             128 (17.5%)                                 61 (17.9%)                                 1.00
  30-day mortality               138 (18.9%)                                 65 (19.2%)                                 0.99

Abbreviations: AF, atrial fibrillation; ICU, intensive care unit; SD, standard deviation; TIA, transient ischemic attack.

Note: Data are presented as *n* (%) or mean (SD) / median (min; max).

Outcome Measures
----------------

Surgical outcome and postoperative complications are shown in [Table 3](#TB180046-3){ref-type="table"} . Reoperation for bleeding was less common among females than in males (16.5% vs. 23.9%, *p*  = 0.005). No difference was observed in intraoperative death among females as compared with males (9.1% vs. 6.7%, *p*  = 0.17), death at discharge (16.4% vs. 16.4%, *p*  = 1.00), or 30-day mortality (17.4% vs. 17.7%, *p*  = 0.99).

In a multivariable logistic regression analysis for 30-day mortality ( [Table 4](#TB180046-4){ref-type="table"} ), no difference was found between females and males in 30-day mortality (OR: 0.92, 95% CI: 0.62--1.38, *p*  = 0.69).

###### Univariable and multivariable logistic regression analyses for 30-day mortality

                                                       Univariable [a](#FN180046-9){ref-type="table-fn"}   Adjusted [b](#FN180046-10){ref-type="table-fn"}   Multivariable [c](#FN180046-11){ref-type="table-fn"}                                                                                                              
  ---------------------------------------------------- --------------------------------------------------- ------------------------------------------------- ------------------------------------------------------ -------------------- ----------- ------------------- -------------------- ----------- -------------------- -----------
  Gender                                               0                                                   Male                                              138 (17.7%)                                                                                                                                                       
                                                                                                           Female                                            65 (17.4)                                              0.98 (0.71--1.36)    0.92        0.50 (0.47--0.54)   0.90 (0.65--1.25)    0.53        0.92 (0.62--1.38)    0.69
  Age (OR per 5 units)                                 0                                                   14.0--\< 58.0                                     54 (14.4)                                                                                                                                                         
                                                                                                           58.0--\< 68.0                                     65 (17.0)                                                                                                                                                         
                                                                                                           68.0--86.0                                        84 (21.2)                                              1.09 (1.02--1.16)    0.011       0.57 (0.52--0.61)   1.09 (1.02--1.16)    0.011       1.06 (0.98--1.15)    0.15
  Age \> 70 y                                          0                                                   No                                                141 (16.3)                                                                                                                                                        
                                                                                                           Yes                                               62 (21.3)                                              1.39 (0.99--1.94)    0.055       0.53 (0.50--0.57)   1.03 (0.65--1.64)    0.88                             
  BMI (OR per 5 units)                                 198                                                 11.39--\< 24.49                                   39 (12.3)                                                                                                                                                         
                                                                                                           24.49--\< 27.80                                   49 (15.4)                                                                                                                                                         
                                                                                                           27.80--53.88                                      52 (16.2)                                              1.18 (0.99--1.41)    0.069       0.55 (0.50--0.60)   1.22 (1.02--1.47)    0.031                            
  Smoking                                              306                                                 No                                                70 (14.7)                                                                                                                                                         
                                                                                                           Yes                                               55 (14.8)                                              1.01 (0.69--1.48)    0.95        0.50 (0.45--0.55)   1.03 (0.70--1.51)    0.89                             
  Hypertension                                         2                                                   No                                                82 (14.7)                                                                                                                                                         
                                                                                                           Yes                                               120 (20.1)                                             1.46 (1.07--1.98)    0.017       0.55 (0.51--0.58)   1.39 (1.02--1.89)    0.040       1.22 (0.83--1.78)    0.31
  Hypercholesterolemia                                 8                                                   No                                                171 (16.9)                                                                                                                                                        
                                                                                                           Yes                                               28 (20.7)                                              1.29 (0.82--2.01)    0.27        0.51 (0.49--0.54)   1.20 (0.76--1.88)    0.44                             
  Diabetes                                             5                                                   No                                                191 (17.0)                                                                                                                                                        
                                                                                                           Yes                                               11 (42.3)                                              3.58 (1.62--7.91)    0.0016      0.52 (0.50--0.54)   3.34 (1.51--7.41)    0.0030      3.57 (1.15--11.05)   0.027
  COPD                                                 4                                                   No                                                181 (16.7)                                                                                                                                                        
                                                                                                           Yes                                               21 (30.4)                                              2.18 (1.27--3.72)    0.0046      0.53 (0.50--0.55)   2.02 (1.18--3.48)    0.011       1.99 (1.02--3.85)    0.043
  HxStroke                                             3                                                   No                                                191 (17.3)                                                                                                                                                        
                                                                                                           Yes                                               11 (23.4)                                              1.46 (0.73--2.92)    0.28        0.51 (0.49--0.53)   1.36 (0.68--2.74)    0.38                             
  HxTIA                                                4                                                   No                                                199 (17.6)                                                                                                                                                        
                                                                                                           Yes                                               3 (17.6)                                               1.01 (0.29--3.53)    0.99        0.50 (0.49--0.51)   0.94 (0.27--3.32)    0.93                             
  HxCKD                                                4                                                   No                                                197 (17.4)                                                                                                                                                        
                                                                                                           Yes                                               5 (23.8)                                               1.48 (0.54--4.08)    0.45        0.50 (0.49--0.52)   1.59 (0.57--4.42)    0.37                             
  HxAfib                                               649                                                 No                                                68 (14.2)                                                                                                                                                         
                                                                                                           Yes                                               7 (25.9)                                               2.11 (0.86--5.18)    0.10        0.52 (0.49--0.56)   1.98 (0.80--4.93)    0.14                             
  Marfan syndrome                                      4                                                   No                                                197 (17.9)                                                                                                                                                        
                                                                                                           Yes                                               5 (10.2)                                               0.52 (0.20--1.33)    0.17        0.51 (0.50--0.52)   0.65 (0.25--1.68)    0.37                             
  Preoperative creatinine (µmol/L) (OR per 10 units)   195                                                 6.2--\< 79.0                                      37 (11.5)                                                                                                                                                         
                                                                                                           79.0--\< 102.0                                    41 (12.9)                                                                                                                                                         
                                                                                                           102.0--1000.0                                     76 (24.0)                                              1.07 (1.03--1.11)    0.0007      0.61 (0.56--0.66)   1.07 (1.03--1.11)    0.0007                           
  Euroscore II (OR per 5 units)                        851                                                 0.62--\< 4.10                                     8 (7.9)                                                                                                                                                           
                                                                                                           4.10--\< 11.10                                    19 (18.4)                                                                                                                                                         
                                                                                                           11.10--65.44                                      30 (30.3)                                              1.26 (1.11--1.43)    0.0003      0.67 (0.60--0.75)   1.22 (1.07--1.40)    0.0025                           
  LVEF TEE (%) (OR per 5 units)                        752                                                 0.0--\< 50.0                                      26 (19.4)                                                                                                                                                         
                                                                                                           50.0--\< 55.0                                     12 (8.9)                                                                                                                                                          
                                                                                                           55.0--74.0                                        13 (9.8)                                               0.78 (0.67--0.91)    0.0011      0.62 (0.52--0.71)   0.78 (0.67--0.91)    0.0011                           
  Cardiac arrest                                       4                                                   No                                                180 (16.5)                                                                                                                                                        
                                                                                                           Yes                                               22 (38.6)                                              3.19 (1.83--5.56)    \< 0.0001   0.54 (0.51--0.56)   3.18 (1.82--5.55)    \< 0.0001   1.64 (0.82--3.30)    0.16
  Hypotensive shock at presentation                    84                                                  No                                                126 (15.4)                                                                                                                                                        
                                                                                                           Yes                                               65 (25.8)                                              1.91 (1.36--2.68)    0.0002      0.56 (0.53--0.60)   1.85 (1.32--2.61)    0.0004      0.76 (0.45--1.28)    0.30
  Pericardial tamponade                                26                                                  No                                                145 (15.5)                                                                                                                                                        
                                                                                                           Yes                                               55 (28.9)                                              2.23 (1.55--3.19)    \< 0.0001   0.56 (0.53--0.60)   2.15 (1.50--3.09)    \< 0.0001   1.17 (0.73--1.86)    0.52
  DeBakey class                                        8                                                   I                                                 153 (18.1)                                                                                                                                                        
                                                                                                           II                                                44 (14.5)                                              0.77 (0.53--1.10)    0.15        0.52 (0.49--0.56)   0.71 (0.49--1.03)    0.074                            
  Penn class                                           10                                                  Penn class A vs. Penn class A                     77 (10.9)                                              1.00                                                 1.00                             1.00                 
                                                                                                           Penn class B vs. Penn class A                     52 (21.2)                                              2.20 (1.49--3.24)    \< 0.0001                       2.24 (1.52--3.31)    \< 0.0001   2.31 (1.47--3.65)    0.0003
                                                                                                           Penn class C vs. Penn class A                     43 (34.1)                                              4.23 (2.73--6.55)    \< 0.0001                       4.18 (2.69--6.49)    \< 0.0001   4.35 (2.38--7.97)    \< 0.0001
                                                                                                           Penn class B and C vs. Penn class A               29 (42.6)                                              6.06 (3.55--10.36)   \< 0.0001   0.66 (0.62--0.70)   6.37 (3.71--10.94)   \< 0.0001   6.61 (3.24--13.52)   \< 0.0001
  CPB time (OR per 30 units)                           96                                                  0--\< 168                                         43 (12.1)                                                                                                                                                         
                                                                                                           168--\< 219                                       43 (12.4)                                                                                                                                                         
                                                                                                           219--715                                          90 (25.2)                                              1.23 (1.16--1.30)    \< 0.0001   0.64 (0.59--0.69)   1.23 (1.16--1.30)    \< 0.0001   1.22 (1.15--1.30)    \< 0.0001
  Cross-clamp time (OR per 10 units)                   126                                                 0--\< 76                                          45 (13.0)                                                                                                                                                         
                                                                                                           76--\< 116                                        42 (12.4)                                                                                                                                                         
                                                                                                           116--364                                          83 (24.3)                                              1.07 (1.04--1.10)    \< 0.0001   0.59 (0.54--0.65)   1.07 (1.05--1.10)    \< 0.0001                        

Abbreviations: Afib, atrial fibrillation; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; Hx, history of; LVEF, left ventricular ejection fraction; OR, odds ratio; ROC, receiver operating characteristic; TEE, transthoracic echocardiogram; TIA, transient ischemic attack.

Note: *p* -Values, OR, and area under ROC-curve are based on original values and not on stratified groups. OR is the ratio for the odds for an increase of the predictor of one unit. Area under ROC-curve with 95% CI for multivariable model is equal to 0.75 (0.71--0.79).

All tests were performed with univariable logistic regression.

Adjusting for age using logistic regression.

Multivariable logistic regression model including sex, age, hypertension, diabetes, COPD, cardiac arrest, hypotensive shock at presentation, pericardial tamponade, Penn class, and CPB time.

Discussion
==========

In this study, we found no sex-related difference in early survival among patients who had undergone surgical repair for ATAAD. Females represented one-third of the cohort and were on average 5 years older, had lower BMI, and had more frequently a history of hypertension and COPD. Furthermore, CPB and HCA times were shorter among females, who less frequently underwent aortic valve replacement, compared with males.

Female sex has previously been suggested as a risk factor in patients undergoing surgical repair for ATAAD. However, most previous reports have included small cohorts, often involving heterogeneous patient populations, and have shown diverging results. [@JR180046-3] [@JR180046-9] [@JR180046-10] A limited number of multicenter studies, including the International Registry of Acute Aortic Dissection (IRAD), have examined the association between sex and outcome following surgical repair for aortic dissection. In the IRAD registry, Nienaber et al [@JR180046-9] found a significantly higher in-hospital mortality among females as compared with males (30.1% vs. 21.0%). However, the study included a heterogeneous group of patients with Stanford Type A and B dissections that were treated either medically and/or surgically. When adjusting for Type A aortic dissection, females still presented worse outcome. The increased mortality among females was suggested to be due to worse preoperative characteristics and an increased time-delay from symptom presentation to diagnosis as compared with males, although no risk-adjusted analysis was presented.

In this study, we found a shorter delay in the time duration from symptom presentation until definitive treatment with surgery among females than that for males, yet not statistically significant. A shorter delay in diagnosis could indicate that females were more inclined to seek medical attention on recognition of symptoms. However, as for ischemic heart disease, females often present with more atypical symptoms of ATAAD, resulting in misdiagnosis and treatment for other more common conditions, such as acute coronary syndrome. [@JR180046-13] [@JR180046-14] [@JR180046-15] It is well defined that the mortality rate increases significantly with time in patients with ATAAD, and a delay in diagnosis can have fatal consequences. [@JR180046-14]

In a recent study by Melvinsdottir et al [@JR180046-16] that included both surgical cases and those diagnosed at autopsy, 35% of all patients with ATAAD died prior to hospital arrival. In consistency, another study reported that 49% of patients with ATAAD had died before hospital assessment, whereof 61% were females. [@JR180046-17] Death prior to hospital arrival may have influenced our results as we did not include these patients in this study, thus possibly underestimating the incidence of ATAAD and early fatality. Furthermore, females are found to be older than males at the onset of ATAAD and therefore may have been more prone to medical management as opposed to surgery. [@JR180046-18]

The study by Lee et al investigated operative management and outcomes of 2,983 patients with ATAAD in North America. They found that both age above 70 years and female sex were independent predictors of mortality, in spite of the higher occurrence of ATAAD among males in their study. Nevertheless, the mean age for females and males was not reported, and the primary aim was not to study the effects of sex on outcome. [@JR180046-3] In most previous studies, the occurrence of ATAAD has consistently been lower among females (with a ratio of 1:2 or 1:3), who have also been found to be older with an average age difference of 7 to 11 years [@JR180046-4] [@JR180046-5] [@JR180046-9] [@JR180046-10] [@JR180046-11] [@JR180046-16] and have lower BMI as compared with males. [@JR180046-4] [@JR180046-5] In consistency with previous studies, females were also significantly older, had lower BMI, and more frequently had a history of hypertension and COPD in the present cohort. Females also presented with significantly lower preoperative creatinine, although within the normal range. Interestingly, and despite these variances in patient characteristics, we found no difference in mortality among sexes. When adjusting for perioperative factors in a multivariable analysis, no difference was found between sexes in 30-day mortality. In the same analysis, a history of preoperative diabetes and COPD had an effect on mortality. This however did not seem to affect outcome in females, who more frequently presented with a history of COPD.

Extensive aortic repair including aortic root and/or valve replacement and/or aortic arch repair may also influence outcome prognosis in patients. Nevertheless, and in contrast to the NORCAAD, intraoperative characteristics were not reported in most of the previous studies on sex differences in ATAAD. [@JR180046-4] [@JR180046-9] [@JR180046-10] [@JR180046-11] In this study, HCA time were shorter among females. This could be due to the increased incidence of total arch procedures in males, although not statistically significant. Furthermore, DeBakey Type I dissections were more frequent among males, indicating a more widespread dissection of the aortic arch and distal aorta. Females less frequently underwent extensive repair with valve replacement compared with males, which most likely explains the shorter duration of operation, CPB, and aortic cross-clamp time in females. Alternatively, it could indicate that simplified procedures (supracoronary graft alone) were more often performed in females, and if so, possible sex bias. Such sex bias may have acted in a favorable direction: greater age and increased preoperative comorbidity thus counteracted by a swifter surgical procedure resulting in equalized early mortality.

A longer life span among females may have contributed to the increased occurrence of comorbidities such as hypertension. [@JR180046-4] The incidence of hypertension, which increases with age, is believed to play an important role in the pathogenesis of ATAAD. However, and in consistency with previous studies, the incidence of ATAAD for males was twice that for females, implying that females may be less prone to the development of ATAAD.

Limitations and Strengths
-------------------------

This study included a subset of patients who reach designated tertiary referral centers alive. This is an important limitation, as a substantial proportion of patients with ATAAD who died prior to hospital admission may have been missed, thereby underestimating overall incidence and outcome. Importantly, data on the time duration from the onset of symptoms until the surgical treatment were often missing; therefore, these results have to be interpreted carefully. Differences may have been present in the surgical techniques used over time or among the different institutions; however, our multicenter study allowed us to include a large cohort of surgical patients with Stanford Type A dissection. Furthermore, the uniform health care systems in the Nordic countries ensured a relatively stable homogeneous populations for which follow-up was successfully achieved.

Conclusions
===========

In summary, this study, which is one of the largest to date, found no sex-related differences in early mortality following surgery for ATAAD. This is seen despite females being older and having more comorbidities, but also presenting with less widespread dissection than males. In line with previous studies, females represented only one-third of the cohort, implying that females may be better protected from the development of ATAAD.
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